Topiroxostat
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 24, 2014 (NCT02327754)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Xanthine dehydrogenaseINHIBITOR
XDH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1cc(-c2n[nH]c(-c3ccncc3)n2)ccn1- Mol. weight
- 248.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1078685 ↗
Also known as
- 4-(5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
- 4-(5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
- 4-(5-pyridin-4-yl-1h-(1,2,4) triazol-3-yl)pyridine-2-carbonitrile
- fyx-051
- fyx-051
- topiloric
- topiroxostat
- topiroxostat
- topiroxostat
- topiroxostat
- topiroxostat
- topiroxostat
- topiroxostat
- uriadec
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02837198 | Phase 2 | Jul 1, 2016 | Fuji Yakuhin Co., Ltd. |
| NCT02327754 | Phase 2 | Dec 24, 2014 | Fuji Yakuhin Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fuji Yakuhin Co., Ltd. | For profit | 2 | 1 | 1 | 2014 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1